Anaemia of chronic disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anaemia of chronic disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis https://clinicaltrials.eu/trial/study-on-efepoetin-alfa-and-darbepoetin-alfa-for-treating-anemia-in-patients-with-chronic-kidney-disease-on-dialysis/ Wed, 29 Apr 2026 14:58:45 +0000 https://clinicaltrials.eu/trial/study-on-efepoetin-alfa-and-darbepoetin-alfa-for-treating-anemia-in-patients-with-chronic-kidney-disease-on-dialysis/ This clinical trial is focused on studying the treatment of anemia in patients with chronic kidney disease who are on dialysis. Anemia is a condition where the body does not have enough healthy red blood cells to carry adequate oxygen to the body’s tissues, often leading to fatigue and weakness. Chronic kidney disease is a long-term condition where the kidneys do not work as well as they should. Dialysis is a treatment that takes over the job of the kidneys when they fail. The study will compare the effectiveness and safety of a new medication called efepoetin alfa (also known by the code name GX-E4) with an existing medication called darbepoetin alfa, which is marketed under the name Aranesp. Both medications are solutions for injection and are used to help increase red blood cell production in the body.

The purpose of the study is to evaluate how well efepoetin alfa controls hemoglobin levels compared to darbepoetin alfa in patients undergoing hemodialysis. Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. The study will involve participants receiving either efepoetin alfa or darbepoetin alfa through intravenous injections over a period of up to 52 weeks. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study aims to determine if efepoetin alfa is not inferior to darbepoetin alfa in maintaining stable hemoglobin levels in these patients.

Throughout the study, participants will have their hemoglobin levels monitored regularly to assess the effectiveness of the treatment. The study will also observe any side effects or safety concerns associated with the medications. By the end of the study, researchers hope to gather enough information to understand whether efepoetin alfa is a viable alternative to darbepoetin alfa for treating anemia in patients with chronic kidney disease on dialysis.

]]> Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis https://clinicaltrials.eu/trial/study-on-efepoetin-alfa-and-darbepoetin-alfa-for-treating-anemia-in-patients-with-chronic-kidney-disease-on-dialysis-2/ Wed, 29 Apr 2026 14:57:07 +0000 https://clinicaltrials.eu/trial/study-on-efepoetin-alfa-and-darbepoetin-alfa-for-treating-anemia-in-patients-with-chronic-kidney-disease-on-dialysis-2/ This clinical trial is focused on studying the treatment of anemia in patients with chronic kidney disease who are on dialysis. Anemia is a condition where the body does not have enough healthy red blood cells to carry adequate oxygen to the tissues, which can make a person feel tired and weak. Chronic kidney disease is a long-term condition where the kidneys do not work as well as they should. The study will compare the effectiveness and safety of a new treatment called efepoetin alfa (also known by the code name GX-E4) with an existing treatment called darbepoetin alfa, which is marketed under the name Aranesp.

The purpose of the study is to evaluate how well efepoetin alfa controls hemoglobin levels in patients. Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. The study will involve patients receiving either efepoetin alfa or darbepoetin alfa through intravenous injections. The study will last for a period of 52 weeks, during which the patients’ hemoglobin levels will be monitored to see if efepoetin alfa is as effective as darbepoetin alfa in maintaining these levels.

Participants in the study will receive regular injections and have their health closely monitored by healthcare professionals. The study aims to provide valuable information on whether efepoetin alfa can be a safe and effective alternative to current treatments for anemia in patients with chronic kidney disease on dialysis. This research could potentially lead to improved treatment options for managing anemia in these patients.

]]>